TEMPO study further demonstrates the benefits of Azilect in early Parkinson's disease patients
Newly published data confirms long term efficacy, safety and tolerability in treating early Parkinson's disease
09-Aug-2010 -
H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's ...
dopamine agonists
Lundbeck
medicine
+4